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ABSTRACT
Flightless I (Flii) is an actin remodeling protein that affects cellular processes 
including adhesion, proliferation and migration. In order to determine the role of 
Flii during carcinogenesis, squamous cell carcinomas (SCCs) were induced in Flii 
heterozygous (Flii+/−), wild-type and Flii overexpressing (FliiTg/Tg) mice by intradermal 
injection of 3-methylcholanthrene (MCA). Flii levels were further assessed in biopsies 
from human SCCs and the human SCC cell line (MET-1) was used to determine the effect 
of Flii on cellular invasion. Flii was highly expressed in human SCC biopsies particularly 
by the invading cells at the tumor edge. FliiTg/Tg mice developed large, aggressive SCCs in 
response to MCA. In contrast Flii+/− mice had significantly smaller tumors that were less 
invasive. Intradermal injection of Flii neutralizing antibodies during SCC initiation and 
progression significantly reduced the size of the tumors and, in vitro, decreased cellular 
sphere formation and invasion. Analysis of the tumors from the Flii overexpressing mice 
showed reduced caspase I and annexin V expression suggesting Flii may negatively 
regulate apoptosis within these tumors. These studies therefore suggest that Flii 
enhances SCC tumor progression by decreasing apoptosis and enhancing tumor cell 
invasion. Targeting Flii may be a potential strategy for reducing the severity of SCCs.
INTRODUCTION
Cutaneous squamous cell carcinomas (SCCs) 
are invasive, recurrent and in some cases potentially 
metastatic [1, 2]. Identifying new target proteins that 
inhibit cancer cell invasion and stimulate tumor apoptosis 
could lead to new treatments to reduce the severity of 
SCCs. Dynamic actin remodeling, alterations in cell 
morphology, apoptosis, adhesion and motility are all 
crucial aspects of tumor cell invasion and metastasis 
[3–6]. It has long been known that the actin cytoskeleton 
is deregulated in tumor cells and the cytoskeleton has been 
linked to aberrant tumor-microenvironment interactions in 
cutaneous SCC [4–8]. Flightless I (Flii), a multifunctional 
actin remodeling protein, has been identified as a tumor 
promoter with transcriptional activity in colorectal, breast 
and hepatocellular carcinoma cell lines [9, 10]. Flii is a 
member of the gelsolin family of cytoskeletal proteins that 
controls actin by severing pre-existing filaments and/or 
capping filament ends to enable filament reassembly into 
new cytoskeletal structures [11, 12]. Numerous cellular 
activities have been shown to involve Flii including the 
regulation of transcription via co-activation of nuclear 
hormone receptors [13–15], type I collagen gene [15], 
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PPARy [16], and the regulation of β-catenin-dependent 
transcription [12]. Flii suppresses proliferation via 
interactions with calmodulin-dependent protein kinase 
type II [17], inflammation, and cytokine production via 
effects on Toll-like receptor signaling [18–20]. In addition, 
Flii effects on inflammation are facilitated by inhibition 
of caspase activation and suppression of IL-1beta 
maturation and caspase-1 mediated apoptosis [21, 22]. 
Actin polymerization can be inhibited by Flii as it forms a 
“cap” to prevent further elongation of the actin polymers 
which are necessary for cellular locomotion [23]. Flii 
stabilizes focal adhesions and over-expression leads to 
a decrease in the hemi-desmosome component CD151, 
laminin-332 and altered expression of laminin integrin 
receptors α3β1 and α6β4 [24]. Increased expression of 
Flii also impairs focal adhesion turnover in a Rac1 reliant 
manner and enhances formation of fibrillar adhesions [25] 
while promoting reduced cell spreading and elongated 
protrusion formation enabling collagen remodeling 
[26]. Through its bipartite domain structure, Flii is able 
to bind with numerous structural and signaling proteins 
at the basement membrane and transduce cell signaling 
events into cytoskeletal remodeling, inhibiting integrin 
facilitated stable anchoring contacts and active turnover 
of focal adhesions [25]. Interestingly Flii is also secreted 
in response to tissue injury [27]. Its extracellular function 
has been linked to regulation of tissue inflammation 
and reducing its expression using the application of 
neutralizing antibodies results in improved healing 
of wounds [28–31]. Indeed, the association between 
regulators of wound healing, inflammation and cancer 
have been well established [32, 33]. In addition, the 
function of Flii as a nuclear receptor co-activator and its 
involvement in different cell signaling pathways whereby 
it alters extracellular matrix composition and promotes 
tissue scarring suggests a potential promoting activity for 
Flii in tumor growth and spread [34–36]. Furthermore, a 
number of studies have shown that the expression levels 
of actin remodeling proteins oscillate during tumor 
progression and that therapies targeting those proteins may 
inhibit cell motility and invasion [3, 9, 37, 38].
In this study, we have investigated the effect of 
Flii on SCC development and determined the effect of 
reducing Flii both genetically and using Flii-neutralizing 
antibodies (FnAb) on SCC development and tumor 
progression.
RESULTS
Human and murine cutaneous SCCs have 
elevated levels of Flii
Human SCC biopsies were collected from patients 
with invasive cutaneous SCC following pathologist 
diagnosis. They showed pathological features of invasive 
cutaneous SCC including anastomosing nests and strands 
of atypical keratinocytes originating in the epidermis 
and infiltrating deep into the dermis with evidence 
of intracellular bridges, parakeratosis and horn pearl 
formation (Supplementary Figure S1). Flii expression 
was significantly elevated in the human invasive 
cutaneous SCC compared to normal human skin with 
positive staining observed in the invading keratinocytes, 
surrounding tumor stroma and outer hyperkeratotic 
layer of the SCC nodules present in the deep dermis 
(Figure 1A). Flii expression was also observed in murine 
invasive cutaneous SCC samples with elevated Flii 
staining observed in both invading keratinocytes and 
dermal fibroblasts surrounding the tumor when compared 
to normal control skin (Figure 1B). Serum samples 
were collected from three patients with SCC and the 
level of secreted Flii determined. Compared to normal, 
commercially available, human serum, Flii levels were 
significantly elevated with an increase of 74.87% +/− 
30.19% observed (Figure 1C).
Severe SCCs develop when flii levels are elevated
Cutaneous SCCs were induced in Flii+/−, wild-
type and FliiTg/Tg mice by a single intradermal injection 
of MCA. Flii+/− mice with only one copy of the gene 
have half the amount of Flii protein compared to WT 
while FliiTg/Tg with two extra copies of the gene have 
1.52 fold increased levels of Flii protein in the skin 
[39]. Flii heterozygous mice had significantly smaller 
tumor areas compared to wild-type counterparts at day 
49 and 52 of the experiment, with both groups of mice 
showing superficial moderate to well differentiated tumor 
papules, hyperchromatic nuclei and epidermal atypia 
(Figure 2A–2D). In contrast, from day 66 onwards, 
tumors on the FliiTg/Tg mice greatly increased in both area 
(≤ 2 fold increase) (Figure 2A–2B) and volume (≤ 3 fold 
increase) (Figure 2E) compared to WT and Flii+/− mice. 
At day 84 when the trial was completed, the tumors were 
assessed histologically with larger, well differentiated 
tumors with extracellular keratin pearls and intercellular 
bridges observed in the FliiTg/Tg mice compared to both 
wild-type and Flii+/− mice (Figure 2C–2D). Flii expression 
was increased by 31.03% +/− 8.25% in SCCs of FliiTg/Tg 
mice compared to SCC in wild-type mice (Figure 2G). 
The severe development of SCC in FliiTg/Tg mice was 
confirmed using cytokeratin staining with cytokeratin 
positive hyperkeratotic nodules and significantly longer 
tumor epithelium observed in FliiTg/Tg compared to wild-
type and Flii+/− mice (Figure 2C, 2D and 2F).
Tumors in FliiTg/Tg mice have decreased markers 
of apoptosis
Cutaneous SCCs induced in Flii+/−, wild-type and 
FliiTg/Tg mice were stained for markers of proliferation 
(PCNA (Figure 3A–3B)), and apoptosis (Caspase-1, 
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Annexin-V (Figure 4A–4C)). No differences were 
observed in the numbers of PCNA positive proliferating 
cells between the tumors originating from the Flii+/−, 
wild-type or FliiTg/Tg mice suggesting that Flii is not 
directly affecting cell proliferation in these tumors. 
(Figure 3A–3B). Caspase 1 and Annexin-V were 
significantly decreased in FliiTg/Tg SCCs (Figure 4A–4C) 
compared to wild-type and Flii+/− mice tumors sugges-
ting that high Flii levels may aid in tumor evasion of 
apoptosis in Flii overexpressing mice.
Figure 1: Flightless protein levels are increased in invasive cutaneous SCC. A–B. Immunofluorescence analysis of Flii 
(greyscale in signal channel images and green in Merge) expression in normal margin skin and invasive cutaneous SCC of human 
(A, N = 21) or murine (B, N = 5) origin. Cytokeratin 14 (K14) immunofluorescence (greyscale in signal channel images and red in Merge) 
marks keratinocytes. Box and whisker plots show the median, range and quartiles of area coverage analysis carried out on the green channel 
to quantify Flii expression. Statistical significance was calculated using the Mann-Whitney test with Dunnet’s post hoc test. *** P < 0.001. 
Magnification ×10 Insert ×20. Scale Bar = 100 μm C. Levels of secreted Flii were also examined in serum of three SCC patients. Flii is 
increased in serum of SCC patients (n = 3) compared to normal human serum (NHS) control. Albumin was used as a loading control. 
Graphical representation of Flii protein expression determined by densitometry. Figure is representative of three independent experiments. 
Mean +/− SD *p < 0.05.
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Figure 2: Overexpression of Flii results in severe SCC development. A–B. Using the MCA induced model of SCC in Flii+/−, WT 
and FliiTg/Tg mice we demonstrate that over-expression of Flii leads to quicker onset and more severe progression of necrotic and ulcerated 
SCC tumor lesions with significantly larger tumor area (n = 12/genotype) Mean +/− SD * and º = P < 0.05. * denotes significance vs FliiTg/Tg 
and º denotes significance vs Flii+/−. C. Epithelial origin of invading cells and hyperkeratotic nodules (red arrows) present in the dermis of 
Flii+/−, WT and FliiTg/Tg SCC induced mice was confirmed with positive cytokeratin staining in all samples. D–F. Representative images 
of tumor margins (dotted green line) in Flii+/−, WT and FliiTg/Tg mice and macroscopic analysis of tumor volume and microscopic analysis 
of length of tumor epithelium revealing significantly larger tumors in Flii over-expressing mice. (n = 12/genotype) Mean +/− SD *P < 0.05. 
t = tumor n = normal skin G. Representative images of increased Flii expression in tumors of FliiTg/Tg mice compared to wild-type controls. 
(n = 12/genotype) Mean +/− SD *P < 0.05. Magnification ×20 and ×10. Scale Bar = 100 μm and 500 μm.
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Exogenous reduction of Flii decreases tumor size 
and progression
Intradermal injections of Flii neutralizing 
antibodies (FnAb) to the tumor site of WT mice at 
week 0, 2, 4, 6 and 8 decreased the tumor size and 
volume compared to control injections of irrelevant IgG 
antibody (Figure 5A). The volume of the tumors was 
measured macroscopically at weekly time points with 
control-treated tumors increasing up to 5 fold at week 
10 in both tumor area and volume compared to FnAb-
treated tumors (Figure 5B–5D). Histological analysis 
confirmed that FnAb treated tumors were significantly 
smaller with decreased length of tumor epithelium and 
cross sectional tumor width (Figure 5E–5F). They further 
showed less invasion, reduced cellular outgrowths and 
limited hyperkeratotic nodule formation (Figure 4C). Flii 
levels were significantly reduced in FnAb treated tumors 
(22.50% +/− 7.53% reduction) and serum (51.57% 
+/− 5.01% reduction) of FnAb treated mice compared 
to control treated tumors and serum of control mice 
respectively (Figure 5G–5H).
Exogenous reduction of Flii prior to SCC 
induction decreases SCC development
Flii is elevated in SCCs of human and murine 
origin (Figure 1) and increased expression of Flii 
escalates the size and progression of tumor formation 
(Figure 2). Flii levels are elevated in FliiTg/Tg mice 
therefore to determine if reducing the level of Flii prior 
to SCC formation reduced the size and progression of 
tumors, FnAbs were intradermally injected into the 
dorsal skin of FliiTg/Tg mice for two weeks prior to SCC 
initiation and then every two weeks until week 10 when 
the study was completed with the aim to maintain low 
levels of Flii within the skin. The resulting tumors of 
FnAb treated FliiTg/Tg mice were significantly smaller than 
IgG controls and comparable to those of untreated wild-
type mice (Figure 6A). Tumor area and volumes were 
up to 2.5 fold smaller than IgG treated mice (Figure 6B–
6D). While microscopic analysis showed no significant 
difference in microscopic length of tumor epithelium 
(Figure 6E), FnAb treated tumors were confirmed to 
be significantly smaller with significantly smaller cross 
Figure 3: Flii does not influence the proliferation of cutaneous SCC tumors. A–B. Cutaneous SCC tumors in Flii+/−, WT and 
FliiTg/Tg mice were stained for PCNA and number of positive proliferating cells analysed showing no effect of Flii on tumor proliferation. 
(n = 12/genotype). Magnification × 20. Scale Bar = 100 μm. Mean +/− SD *P < 0.05.
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sectional tumor width (Figure 6F). FliiTg/Tg FnAb treated 
tumors had significantly reduced Flii expression (24.53% 
+/− 8.35% reduction) compared to IgG treated controls 
(Figure 6G) and similar levels as observed in untreated 
wild-type SCC tumors (Figure 6G).
Reducing Flii decreases SCC tumor sphere 
formation and keratinocyte invasion in-vitro
Flii levels were significantly elevated (130% 
+/− 66% increase) in MET-1 SCC cells compared to 
HaCaTs (Figure 7A). Flii levels in MET-1 SCC cells 
were further compared to MET-2 (cells from recurrent 
tumor of same patient) and MET-4 (cells from metastatic 
tumor of same patient) SCC cell lines (Figure 7B). 
No significant difference in Flii levels were observed 
between these different SCC cell lines. MET-1 SCC 
keratinocytes were assessed for the effect of FnAb on 
sphere formation. The effect of attenuating Flii on tumor 
microenvironment and sphere formation was determined 
with significantly smaller sphere areas observed at 
both day 5 and day 10 post seeding, when compared 
to IgG treated controls (Figure 7C). Additionally, 
using an organotypic model of cell invasion in three 
Figure 4: High levels of Flii lead to an evasion of apoptosis in cutaneous SCC tumors. A–C. Cutaneous SCC tumors in 
Flii+/−, WT and FliiTg/Tg mice were stained for caspase-1 and Annexin-V markers of apoptosis and number of positive cells analysed showing 
significantly decreased levels of apoptosis in tumors of Flii overexpressing mice. (n = 12/genotype). Magnification ×20. Scale Bar = 100 μm. 
Mean +/− SD *P < 0.05.
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dimensions (3D), the effect of reduced Flii expression 
on MET-1 SCC keratinocytes was investigated in-vitro. 
Addition of FnAb resulted in a significant reduction 
in invasion of MET-1 SCC keratinocytes into the 
collagen/matrigel matrix compared to IgG treated 
controls (Figure 7D–7E) with a reduction of 63.81% +/− 
1.92% observed (Figure 7D–7E). Immunofluorescence 
staining of the 3D organotypic gels showed that Flii 
(green) was present throughout the epidermis and 
co-localized with cortactin (orange) which is a marker of 
Figure 5: Reducing Flii expression during SCC initiation and development using FnAb results in decreased SCC 
progression. WT mice were treated with FnAb at time of SCC induction and every second week throughout the trial. A–B. Examining the 
effect of reducing Flii levels using FnAb at time of SCC induction and during development resulted in decreased tumor progression and delayed 
development with significantly smaller tumor volume. (n = 12/treatment) Mean +/− SD *P < 0.05. C. Representative images of H&E stained 
tumor sections treated with FnAb and IgG control show smaller tumor size and less advanced tumor histology with less invasion, outgrowth and 
hyperkeratotic nodule formation. Magnification ×4 Insert ×20. Scale Bar = 500 μm and 100 μm. D–F. Macroscopic analysis of tumor volume 
and microscopic histological analysis of tumors revealed significantly decreased tumor volume, length of tumor epithelium and cross sectional 
tumor width in FnAb treated tumors. (n = 12/treatment) Mean +/− SD *P < 0.05. G. Representative images and graphical representation of 
significantly reduced Flii expression in FnAb treated tumors compared to IgG treated controls. (n = 12/treatment) Mean +/− SD *P < 0.05. 
H. Western Blot analysis of Flii levels in serum of FnAb treated and IgG control SCC induced wild-type mice showing significant reduction 
in Flii serum levels following FnAb treatment. (n = 3/treatment) Mean +/− SD *P < 0.05. Figure representative of three experimental repeats.
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invadopodia. Flii and cortactin localized together in the 
tumor cells and islets invading into the dermis (yellow) 
(Figure 7F). Flii and cortactin were confirmed to 
associate using anti-cortactin immunoprecipitates derived 
from a confluent culture of MET-1 SCC keratinocytes 
and immunoblotted for Flii (Figure 7G). No association 
was observed between gelsolin and cortactin, despite 
robust expression of gelsolin in MET-1 cells suggesting 
a Flii specific association with the invadopodia marker 
(Figure 7G).
Figure 6: Reducing Flii expression prior to SCC initiation and development using FnAb results in decreased SCC 
progression. As Flii is increased in human SCC samples, effect of preventative FnAb treatment prior to SCC induction was investigated 
in FliiTg/Tg mice. Mice were treated with FnAb two weeks prior to SCC induction and every second week throughout the trial and SCC 
development. A–B. Examining the effect of reducing Flii levels in mice skin using preventative FnAb treatment prior to SCC induction and 
during development resulted in decreased tumor progression and size in FnAb treated mice. IgG control mice have significantly larger and 
more developed necrotic ulcerated tumors. (n = 12/treatment) Mean +/− SD *P < 0.05. C. Representative images of H&E stained tumors 
treated with FnAb or IgG control show more severe ulcerated tumor pathology in IgG control group (black arrows). Magnification ×4 
Insert ×20. Scale Bar = 500 μm and 100 μm. D–F. Macroscopic analysis of tumor volume and microscopic histological analysis of tumors 
revealed no significant difference in length of tumor epithelium however significantly smaller cross tumor volume and cross sectional tumor 
width was observed in FnAb treated tumors. G. Representative images and graphical representation of significantly reduced Flii expression 
in FnAb treated tumors compared to IgG treated controls. (n = 12/treatment) Mean +/− SD *P < 0.05.
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Figure 7: Reducing Flii expression using FnAb reduces sphere formation and invasion properties of SCC keratinocytes 
in-vitro. Flii levels in MET-1 SCC cells were compared to both HaCaT immortalized keratinocyte cell line A. and MET-2 (cells from 
recurrent tumor of same patient) and MET-4 (cells from metastatic tumor of same patient) SCC cell line B. showing significant increase in 
Flii levels in MET-1 SCC cell line compared to HaCaT immortalized keratinocytes. C. The effect of reducing Flii using FnAb (50 μg/ml) 
or dose matched IgG antibody control on MET-1 SCC keratinocyte ability to form tumor spheres was analysed. MET-1 SCC keratinocytes 
treated with FnAb showed a significantly delayed ability and reduced sphere formation. Representative images of sphere size at day 10 
are shown. N = 8. Mean +/− SD *p < 0.05. Scale bar = 500 μm refers to all images. Sporadic SCC cell line, MET-1, was used in a 3D 
organotypic model of cell invasion. Cells were treated with FnAb (50 μg/ml) at time of gel preparation and in media throughout the ten day 
period. D–E. Representative images of H&E stained gels illustrating cell invasion properties. Treatment of MET-1 SCC cells with FnAb 
significantly reduced the cell invasion properties (green arrow) into the gel matrix with 60% decreased depth of invasion. (n = 3/treatment) 
Magnification = 10×. Mean +/− SD *P < 0.05. F. Considering the function of Flii in actin remodelling, Flii association with invadopodia 
marker cortactin was examined using immunohistochemistry. Representative confocal images of dual immunofluorescence of MET-1 
SCC cell lines shown Flii (green) was prominent throughout the epidermis highlighting all SCC cells, while cortactin (orange) was only 
prominent in invading cells highlighting the invadopodia. Flii co-localized with cortactin (yellow) suggesting a tumor promoting activity 
for Flii in SCC cancer cell invasion. Magnification = 400×. G. Anti-cortactin immunoprecipitate (IP) was prepared from confluent MET-1 
SCC cell line and immunoblotted with Flii or Gelsolin (positive control) antibodies. Flii but not Gelsolin was found to associate with 
cortactin and specific bands were observed in MET-1 cell lysate (WCL) control. Data are representative of three independent experiments.
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DISCUSSION
Flii is an important inhibitor of cellular adhesion 
and a promoter of both actin remodeling and cell signaling 
with demonstrated functions in actin polymerization and 
nuclear receptor co-activation respectively [40, 41]. Flii 
colocalizes with actin and microtubule based structures 
[11], controls actin remodeling and polymerization 
[23, 42], stimulates integrin based cell migration [24] and 
controls cell adhesion to extracellular matrix substrates 
[25], all of which are instrumental in the ability of tumor 
cells to migrate and invade surrounding tissue. Here we 
have shown that Flii promotes SCC tumor development 
via its effects on tumor apoptosis and invasion and that 
delayed onset and decreased progression of SCC can be 
achieved by reducing Flii levels in tumors in-vivo.
Flii is increased in human and mouse SCC tissue 
samples, is elevated in the sera of patients with SCC and 
is increased in different SCC cell lines established from 
human primary, recurring and metastatic SCC as well as 
immortalized keratinocytes. Flii over expression resulted 
in larger, more aggressive tumors with an invasive tissue 
pathology. While no metastasis to secondary sites or 
perineural invasion was observed in this model of SCC, 
Flii overexpressing mice did show more differentiated 
tumor pathology compared to wild-type controls. Tumors 
in the Flii overexpressing mice had significantly decreased 
levels of early apoptotic markers annexin-V and pro-
inflammatory caspase-1, potentially indicating reduced 
apoptosis occurring in these tumors which would increase 
SCC tumor progression. Indeed, previous studies have 
described the important suppressive function of Flii as 
an inhibitor of pro-inflammatory caspase activation and 
caspase-1 mediated apoptosis [21, 22]. This literature 
and our results together suggest that the inhibitory effects 
of Flii on caspase-1 activation and apoptosis may aid 
SCC tumor evasion in FliiTg/Tg mice. In contrast, Flii 
heterozygous mice developed less invasive tumors similar 
to those observed in wild-type control mice and showed 
no differences in tumor cell proliferation or apoptosis 
compared to control animals. While Flii levels are 
reduced in heterozygous mice they still retain 50% of gene 
expression which may be sufficient for up-regulation of 
Flii to levels required to initiate tumor formation, however 
these mice did show significantly smaller tumor area and 
decreased length of tumor epithelium compared to both 
wild-type and Flii overexpressing mice. The mouse model 
of SCC used in this study is based on a single intradermal 
injection of the carcinogen MCA and has been used in 
many SCC studies [43–45]. However, our observations 
may be model specific particularly as this model has 
the potential to induce sarcomas if the injection is sub-
cutaneous rather than intradermal. [45].
Reducing Flii expression in SCC tumors in-vivo using 
intradermal injections of FnAb resulted in significantly 
decreased Flii levels in both the tumor microenvironment 
and in the serum and led to significantly smaller tumors, 
both macroscopically and microscopically suggesting that 
reducing Flii may aid in delaying tumor formation and/
or progression. In agreement with these studies, FnAb 
has previously been shown to neutralize Flii activity 
in-vitro and in-vivo [35, 46] and can deplete Flii present 
in conditioned media by over 90% [47]. No studies 
to date have investigated the function of extracellular 
Flii in tumorigenesis however our findings of increased 
Flii levels in invading tumor cells as well as decreased Flii 
serum levels and tumor growth following FnAb treatment 
suggest that Flii may promote tumor development and 
progression. Secretion of gelsolin family members into 
the circulation has previously been linked to functions in 
scavenging actin during tissue injury while Flii secretion 
has been associated with tissue injury and regulation of 
chronic inflammation [28, 48, 49]. The pathway of Flii 
secretion has been characterized [47] but to date no 
Flii cell surface receptors or pathways describing Flii 
impact have been described. Nonetheless, FnAb has been 
shown to be taken up into cells [31] so potentially it may 
neutralize both extracellular and intracellular functions of 
Flii during SCC tumorigenesis.
Remodeling and polymerization of actin filaments 
and their associated actin-binding proteins is important 
in the formation of invadopodia and subsequent tumor 
cell migration and invasion [50]. Increased Flii leads to 
weaker cell-stroma and cell-cell adhesions with altered 
GTPase and Src signaling pathways which may favour 
tumor cell invasion into surrounding tissue [25]. In 
addition, previous studies have demonstrated a function 
for Flii in inhibiting integrin facilitated cell migration, 
with diffuse arrangement of integrin receptors in Flii 
overexpressing keratinocytes contributing to increased 
tumor cell invasion [24]. The tumor promoting activity 
associated with Flii may therefore be due to its effects 
on cell adhesion and migration and its effects on tumor-
microenvironment. A significant decrease in tumor cell 
aggregation/sphere formation and matrix invasion was 
observed following treatment with FnAb in vitro. Flii 
also specifically associated with cortactin, a marker of 
invadopodia. Considering its function in actin remodeling 
and polymerization [23, 41] and its identification as one 
of the proteins present in the invadopodia complex, 
these findings suggest that Flii may promote tumor 
progression, and facilitate invadopodia formation and 
tumor invasion.
Our findings therefore suggest that Flii, like other 
members of the gelsolin family of proteins, can influence 
SCC tumor growth and progression via its effects on 
tumor invasion and apoptosis. These studies identify 
Flii as a novel protein involved in tumor progression 





Mouse monoclonal anti-Flii (sc-21716), anti-cortactin 
E-4 (sc-55888) and anti-vimentin (V9) (sc-6260), rabbit 
polyclonal PCNA (FL-261) (sc-7907), Caspase-1 (M-20) 
(sc-514), Annexin-V (FL-319) (sc-8300) antibodies and 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) 
were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Murine IgG irrelevant (I8765), β-tubulin 
(T0198) and cytokeratin 14 (HPA000452), albumin 
(AO433) antibodies and normal human serum (H3667) 
were obtained from Sigma-Aldrich (Castle Hill, NSW, 
Australia). Alexa-Fluor 488 goat anti-rabbit (A11008) and 
Alexa-Fluor 594 goat anti-mouse (A11020) antibodies 
were obtained from Invitrogen Australia (Waverley, NSW, 
Australia). Gelsolin antibody (610412) was obtained from 
BD Biosciences, NSW, Australia. Mouse monoclonal 
anti-cytokeratin antibody (M0821) was obtained from 
Dako Australia, NSW, Australia. Affinity-purified mouse 
monoclonal anti-Flii (FnAb) IgG1 antibody raised against 
the Leucine-Rich Repeat (LRR) domain of Flii protein 
was made in our laboratory. 3-Methylcholanthrene (MCA) 
(213942) used to induce SCC was obtained from Sigma-
Aldrich (Castle Hill, NSW, Australia).
Cell lines
The human cutaneous invasive SCC keratinocyte 
cell lines from primary tumor (MET-1), reoccurring 
tumor (MET-2) and malignant lesion (MET-4) was 
kindly obtained from Prof Proby and was tested, 
authenticated and characterized by in vitro methods as 
previously described [51]. MET-1 cell line originally 
obtained from the forehead skin of the invasive primary 
tumor in an adult immunosuppressed patient [51] was 
cultured in DMEM:Ham’s F12 (3:1) supplemented 
with 10% FCS, 1% L-glutamine (200 mM) and Ready 
Mix Plus (0.4 μg/ml hydrocortisone, 5 μg/ml insulin, 
10 ng/ml EGF, 5 μg/ml transferrin, 8.4 ng/ml cholera 
toxin and 13 ng/ml liothyronine). The MET-1 cell 
line was derived from primary cutaneous SCC and 
spontaneously immortalised in culture, as previously 
described [51]. Human foreskin fibroblasts (HFFs) 
and human immortalized keratinocytes (HaCaTs) (Cell 
Lines Service, DKFZ, Heidelberg, Germany) were 
cultured in DMEM supplemented with 10% FCS and 1% 
L-glutamine (200 mM). All cells were cultured at 37°C 
with 5% CO2.
Human tissue samples
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board. Human SCC tumors (n = 21) 
were obtained from SA Pathology under oversight of 
the Royal Adelaide Hospital Research Ethics Committee 
(approval number 120113). Human SCC serum (n = 3) 
samples were kindly donated by A/Prof Ian Darby, RMIT 
University, Victoria, Australia under oversight of the St 
Vincent’s Hospital Research Ethics Committee (approval 
number HREC-A 129/09). The clinical investigations 
were conducted according to the Declaration of 
Helsinki principles and written informed consent was 
obtained. The control group for immunohistochemistry 
experiments consisted of human skin samples collected 
during cosmetic surgical procedures (ethics approval 
number 11-CHREC-F007) from four patients with no 
known dermatological conditions. Normal human serum 
(H3667) obtained from Sigma-Aldrich (Castle Hill, NSW, 
Australia) was used as a control for western blotting 
experiments using SCC patient serum.
Animal studies
Mice were maintained according to Australian 
Standards for Animal Care under protocols approved by 
the Child, Youth and Women’s Health Service Animal 
Ethics Committee or the SA Pathology/Central Adelaide 
Local Health Network Animal Ethics Committee. All 
strains were BALB/c or FVB/n congenic and were 
maintained as homozygous colonies or by continuous 
backcross with animals of the relevant pure strain. Wild-
type controls were obtained from BALB/c inbred litters. 
The murine alleles of Flii used in this study were (1) Flii 
tm1Hdc (MGI:2 179 825), a heterozygous carrier of this 
allele is written as Flii+/ − ; and (2) Tg (FLII)1Hdc (MGI:3 
796 828), a transgenic strain expressing exogenous 
human FLII due to the insertion of the human cosmid 
clone c110H8, carriers have two copies of the mouse Flii 
gene and two copies of the human Flii transgene (Flii+/+; 
FliiTg/Tg) denoted throughout this article as FliiTg/Tg [39].
In vivo mouse model of SCC
Cutaneous SCC was induced in 12 week old 
adult female Balb/c Flii+/−, wild-type and FliiTg/Tg mice 
(n = 12 time-point/treatment) following a previously 
published model of cutaneous SCC [44]. Briefly, a single 
intradermal injection of 3-Methylcholanthrene (MCA) 
(500 μg MCA in 100 μl of corn oil) was used to induce 
primary cutaneous SCC. Necrotic and ulcerated SCC 
developed over a 12 week period. At week 12 the mice 
were euthanized and tumor samples collected. SCCs 
were analyzed throughout the trial and at the endpoint 
by a) weekly macroscopic digital images of lesions; 
b) tumor volume measurements using electronic calipers; 
c) histological analysis of tumor invasion and tumor size 
and d) immunofluorescence analysis of Flii, cytokeratin 
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and vimentin expression. Additionally, the effect of 
intradermally administered FnAb on SCC progression in 
WT and FliiTg/Tg mice was performed. Four intradermal 
injections (25 μl) of 100 μl FnAb (50 μg/ml) or IgG 
control were injected into the MCA injection site or 
surrounding the tumor base as it developed at 0, 2, 4, 6 and 
8 weeks (treatment trial) or -2, -1, 0, 2, 4, 6 and 8 weeks 
(prevention trial) (n = 12/treatment). Due to the increased 
SCC tumor growth and development observed in FliiTg/Tg 
mice in the first trial in all subsequent experiments mice 
were euthanized at week 10 of these experiments and 
tumor samples collected.
Multi-stage cutaneous carcinogenesis was 
also carried out as previously described [8]. Briefly, 
dimethylbenz[a]anthracene (DMBA, Sigma, 25 μg) in 
acetone (150 μl) was applied directly to shaved dorsal 
skin. After three days, 12-O-tetradecanoylphorbol-13-
acetate (TPA, Sigma, 6.25 μg) was applied in acetone 
(150 μl) and the application of TPA repeated twice 
weekly for 20 weeks or until an invasive carcinoma 
developed as determined by the conversion of pre-
malignant papillomas of convex shape to a more concave 
appearance. Mice exhibiting carcinomas were humanely 
killed and the tumors dissected out for histological and 
immunohistochemical analysis.
3D organotypic invasion assay
The effect of FnAb on cellular invasion was 
investigated using the sporadic SCC cell line, MET-1, 
in organotypic cultures of collagen:matrigel gels as 
previously described [52]. Briefly, collagen:matrigel 
gels were prepared by mixing 3.5 volumes of type I 
collagen (First Link, UK), 3.5 volumes of Matrigel (BD 
Biosciences, UK), 1 volume of 10× DMEM, 1 volume 
of 10% FCS and 1 volume of DMEM with 10% FCS 
containing 5 × 106/ml HFFs. FnAb (50 μg/ml) or control 
IgG (50 μg/ml) were added to the gel mixture. One ml 
of the gel mixture was placed into each well of a 24-well 
plate and allowed to polymerize at 37°C for 1 hour. After 
polymerization, 1 ml of DMEM was added per well and 
gels were incubated for 18 hours to equilibrate. MET-1 
SCC keratinocytes were then seeded into a plastic ring 
placed on the top of the gel at a density of 5 × 105 cells 
per gel. After 24 hours, the rings were removed and the 
gels raised to air-liquid interface on stainless steel grids. 
Media containing FnAb or dose matched control IgG 
(50 μg/ml) was changed every second day and the gels 
were harvested at day 10, fixed in 4% paraformaldehyde 
(PFA) and embedded in paraffin wax. Histological 
sections (4 μm) were stained with haematoxylin and 
eosin (n = 3/treatment), imaged by light microscopy and 
the depth of cellular invasion quantified using Image 
Pro-Plus computer software (Media Cybernetics Inc., 
Maryland, USA).
Tumor sphere formation assay
The effect of FnAb on MET-1 SCC tumor sphere 
formation was assessed as previously described [53]. 
Briefly, MET-1 SCC cells were seeded in 96-well plates 
coated with 1.5% agarose (Sigma Aldrich, #A3768) 
at 5 × 103 cells per well in complete media containing 
either FnAb (50 μg/ml) or IgG control (50 μg/ml). Media 
containing FnAb or IgG was changed every second day 
and phase contrast images of tumor spheroids captured 
at day 5 and 10 post seeding. Tumor sphere area was 
quantified using Image Pro-Plus computer software 
(Media Cybernetics Inc., Maryland, USA).
Immunohistochemical analysis
Histological sections (4 μm) from paraffin-
embedded fixed human healthy normal skin, human SCC 
tumors, murine MCA-induced Flii+/−, Flii+/+ and FliiTg/
Tg SCC tumors, MET-1 FnAb or IgG treated organotypic 
gels or murine DMBA/TPA induced SCC tumors were 
used for immunofluorescence analysis following antigen 
retrieval according to the manufacturer’s protocols 
(DAKO Corporation, Glostrup, Denmark). Following 
blocking in 3% normal horse serum, primary antibodies 
against Flii, cytokeratin 14, PCNA, CD31, VEGF, 
CD4, CD8, FOXP3, caspase-1, annexin-V and cortactin 
were applied at 1:100 and slides were incubated at 4°C 
overnight in a humidified chamber. The samples were 
subsequently washed 3 × 2 min in PBS before application 
of species specific Alexa Flour-488 or Alexa Flour-594 
secondary antibodies (Invitrogen, Australia) for 1 hr 
at room temperature. Sections were washed 3 × 2 min 
in PBS followed by incubation with DAPI (1:5000) for 
3 min at room temperature. Finally, slides were washed 
in PBS and mounted in Fluorescent Mounting Medium 
(Dako, Australia). Fluorescence intensity per unit area 
was determined using AnalySIS software (Soft Imaging 
System GmbH) and optical fluorescence analyzed 
in epidermis of the skin. InSpeck Microscope Image 
Intensity Calibration Kits (Invitrogen, Carlsbad CA) were 
used to define fluorescence intensity for constructing 
calibration curves and evaluating sample brightness. 
Area coverage analyses in epidermal cells within normal 
and tumor samples were conducted by first masking on 
cytokeratin 14 positive cells (red channel) and measuring 
area coverage within this area in the green (Flii) channel 
as previously described [7, 8]. Negative controls included 
replacing primary antibodies with normal rabbit IgG, 
or normal mouse IgG. For verification of staining, non-
specific binding was determined by omitting primary or 
secondary antibodies. All control sections had negligible 
immunofluorescence.
Histological sections (4 μm) from paraffin-
embedded fixed murine SCC-induced Flii+/−, Flii+/+ and 
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FliiTg/Tg tumors, were used for immunohistochemical 
analysis of cytokeratin to confirm epithelial tumor 
origin following protocols previously described [44, 54]. 
Briefly, sections were quenched in 0.3% H2O2/methanol 
for 20 min prior to blocking in 3% NHS in PBS for 
30 min. Primary antibody was applied to sections at 1:200 
concentration in 3%NHS/PBS overnight in a moist air 
tight container at 4°C. Following PBS washes, species 
specific secondary biotinylated IgG secondary antibody 
was applied to sections at 1:200 concentration for 1 hr at 
room temperature. Following further PBS washes sections 
were subjected to the Vectastain ABC kit following 
manufacturer’s protocol and expression level detected 
using Vector DAB (3,3′-diaminobenzidine) substrate. 
Images of cytokeratin stained tumors were analyzed using 
light microscopy.
Western blotting
Protein was extracted from human serum samples 
and SCC induced or control mice serum samples, 
MET-1 -2, -4 SCC confluent keratinocytes or human 
immortalized HaCaT keratinocytes cell line following 
standard protein extraction protocols. Briefly, samples 
or cells were lysed in lysis buffer (50 mM Tris pH 
7.5, 1 mM EDTA, 50 mM NaCl, 0.5% Triton X-100) 
containing protease inhibitor cocktail tablet (1 per 10 ml; 
Complete, Mini (Roche Products Pty Ltd, Dee Why, 
NSW, Australia)) and samples were homogenized briefly. 
Samples were centrifuged (16 000 × g, 10 min, at 4°C), 
with supernatants being transferred to fresh tubes and 
centrifuged for a further 10 min and the supernatants 
stored at −20°C. Sample protein (10 μg) was run on 10% 
SDS-PAGE gels at 100V for 1 hr and then transferred 
to nitrocellulose by wet transfer (Bio-Rad Laboratories, 
Regents Park, NSW, Australia) using standard Towbins 
Buffer with 20% Methanol at 100V for 1 hr. Membranes 
were blocked in 5% milk-blocking buffer for 10 min and 
primary antibodies added in PBS containing 5% skimmed 
milk powder, 0.3% Tween. Appropriate species-specific 
secondary horseradish peroxidase-conjugated antibodies 
were added for a further 1 hr at room temperature. 
Stringent washes for 1 hr were then performed before 
detection of horseradish peroxidase by Super Signal 
West Femto Maximum Sensitivity Substrate (Pierce 
Biotechnology, Rockford, IL) and capture using GeneSnap 
analysis program (SynGene, MD). Membranes were 
stripped and re-probed for β-tubulin (Sigma-Aldrich) for 
normalization of protein levels.
Co-immunoprecipitation
Tissue lysate was extracted from MET-1 SCC 
keratinocytes following standard extraction protocols as 
described previously [24]. Briefly, confluent cells were 
lysed using a cell scraper and placed in a lysis buffer 
(50 mM Tris pH 7.5, 1 mM EDTA,50 mM NaCl, 0.5% 
Triton X-100) containing protease inhibitor cocktail tablet 
(1 per 10 ml; Complete, Mini (Roche, Australia)). Samples 
were centrifuged and supernatant containing cell lysate 
collected and used for co-immunoprecipitation. The tissue 
lysates were precleared by centrifugation, and incubated 
with 1 μg/μl cortactin antibody and protein G-agarose b 
(Invitrogen) overnight at 4°C. The immunoprecipitates 
were collected by centrifugation, pellets washed with lysis 
buffer, and stored in 2× sample buffer prior to standard 
Western Blotting analysis as previously described [24]. 
Western Blots were probed with Flii antibody or with 
Gelsolin antibody as a negative control. Whole cell lysate 
and beads alone were also loaded as experimental controls.
Statistical analysis
Statistical differences were determined using the 
Student’s t-test or an ANOVA. For data not following 
a normal distribution, the Mann-Whitney U test with 
Dunnet’s post hoc test was performed. A p value of less 
than 0.05 was considered significant.
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